Misoprostol is globally recognized, including by the World Health Organization, as a safe and effective medicine for managing postpartum hemorrhage, incomplete miscarriage, and safe abortion care.
Amplifying Rights Network Position Statement:
The Amplifying Rights Network (ARN) expresses deep concern over ongoing and proposed efforts to tighten restrictions on Misoprostol in Liberia.
As a coalition committed to advancing sexual and reproductive health and rights (SRHR), we firmly believe that placing additional barriers on this essential medicine will reverse hard-won progress in maternal health, increase unsafe practices, and disproportionately harm the most vulnerable.
Misoprostol is globally recognized, including by the World Health Organization, as a safe and effective medicine for managing postpartum hemorrhage, incomplete miscarriage, and safe abortion care. In Liberia, where maternal mortality remains among the highest in the world, estimated at over 1,000 deaths per 100,000 live births, access to life-saving interventions is not optional; it is urgent.
Restricting access to Misoprostol through prescription-only requirements, limited distribution, or policy ambiguity creates delays that can be fatal. In rural communities, where access to doctors and equipped facilities is limited, such policies effectively deny women timely care.
Liberia’s reproductive health landscape already demonstrates the dangers of restrictive policies. The country maintains one of the most restrictive abortion laws in the region, allowing abortion only under limited conditions and requiring approval from multiple medical professionals.
The result has not been fewer abortions but more unsafe ones. An estimated 38,000 abortions occur annually in Liberia, many of them outside formal health systems. Unsafe abortion contributes significantly to maternal deaths, accounting for up to 10–15% of mortality.
This is a critical lesson: restriction does not stop need—it only makes outcomes more dangerous.
Liberia already imposes strict controls on reproductive health medicines. Access to medical abortion drugs including Misoprostol and mifepristone typically requires prescriptions and is limited to licensed providers and facilities.
In practice, this has created delays in accessing care, increased reliance on informal or unregulated markets, and fear among women seeking care due to legal and social consequences.
Research further shows that in restrictive settings like Liberia, women often resort to unsafe methods, leading to severe complications such as sepsis, hemorrhage, and infertility.
The proposed tightening of Misoprostol access follows a broader pattern in Liberia where reproductive health commodities have historically been limited or inconsistently available.
Limited access to contraceptives has contributed to high rates of unintended pregnancies, especially among young women. Gaps in family planning services persist despite policy efforts, with unmet need remaining high. Legal and systemic barriers have restricted access to safe abortion care, even when permitted under law.
These restrictions have collectively driven a cycle of unintended pregnancies, unsafe abortions, and preventable deaths. Introducing further controls on Misoprostol risks deepening this crisis.
The impact of these restrictions will not be evenly distributed. Women in urban areas with financial means may still navigate the system. However rural women will face geographic and logistical barriers, young people will encounter stigma and lack of information, yow-income families will be pushed toward unsafe alternatives.
ARN emphasizes that these policies exacerbate inequality and undermine the principle of equitable healthcare.
Liberia has committed to reducing maternal mortality and improving SRHR outcomes. Partners such as UN agencies continue to support the provision of essential reproductive health commodities and emergency obstetric care.
Restricting Misoprostol directly contradicts these commitments. It weakens health system efficiency, undermines community-based care models, and erodes trust in public health institutions.
The Amplifying Rights Network calls on the Government of Liberia and all stakeholders to:
Reject unnecessary restrictions on Misoprostol and other essential reproductive health medicines
Adopt evidence-based policies that expand safe, community-level access
Strengthen education and awareness to ensure proper use of Misoprostol
Empower midwives and community health workers to provide life-saving care
Liberia’s past and present realities make one thing clear restrictive policies on reproductive health drugs do not protect women they rather put them at risk.
Placing further restrictions on Misoprostol will not reduce its use. It will only drive it underground, increase unsafe practices, and cost lives.
For ARN, the path forward is clear: protect access, protect health, and protect lives